Chimerix Stock

Chimerix Equity

Delisted·Apr 17, 2025

The The Equity of Chimerix (CMRX) as of Aug 26, 2026 is 121.68 M USD. In the previous year, The Equity was 193.03 M USD — a change of -36.96% (lower).

Equity

121.68 MUSD

YoY

-36.96%

Last updated:

In 2026, Chimerix's equity was 121.68 M USD, a -36.96% increase from the 193.03 M USD equity in the previous year.

The Chimerix Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2017
221.81 M USD
Jan 1, 2018
177.60 M USD
Jan 1, 2019
109.95 M USD
Jan 1, 2020
73.38 M USD
Jan 1, 2021
68.25 M USD
Jan 1, 2022
256.86 M USD
Jan 1, 2023
193.03 M USD
Jan 1, 2024
121.68 M USD
The Chimerix Equity history
YEAREquityYoY
121.68 MUSD-36.96%
193.03 MUSD-24.85%
256.86 MUSD+276.34%
68.25 MUSD-6.98%
73.38 MUSD-33.27%
109.95 MUSD-38.09%
177.60 MUSD-19.93%
221.81 MUSD-19.70%
276.22 MUSD-17.66%
335.46 MUSD+22.15%
274.64 MUSD
Access this data via the Eulerpool API

Chimerix Stock analysis

What does Chimerix do? Chimerix Inc is a biopharmaceutical company focused on the development of antiviral drugs. The company was founded in 2002 and is headquartered in Durham, North Carolina. The history of Chimerix dates back to the research of Dr. George Painter, a renowned scientist in the field of antiviral therapy. He discovered that a certain group of molecules, known as nucleoside analogues, have antiviral properties. The idea was to use these molecules as a starting point for the development of drugs that specifically target viruses. The core idea of Chimerix was to create a new business model that is different from traditional pharmaceutical companies. Instead of focusing on the lengthy and costly development of new compounds, the company wanted to utilize existing molecules and create new drugs through targeted modifications. This approach was not only expected to be faster and cost-effective but also to offer higher chances of success. Chimerix is divided into several business segments. The most important segment is antiviral therapy, where the company focuses on developing drugs against various viruses such as Cytomegalovirus (CMV), Adenovirus, and Herpesvirus. Another business segment of Chimerix is oncology. Here, the company also relies on modifying existing compounds to develop new and effective cancer drugs. One promising molecule currently being developed is Brincidofovir, which not only has antiviral properties but also possesses antitumor properties. In addition to drug development, Chimerix also offers support for clinical trials. The company collaborates with various research institutions and biopharmaceutical companies to test the efficacy and safety of new compounds. The most well-known product of Chimerix is Brincidofovir. This antiviral drug is currently being tested in clinical trials and has the potential to be used against a range of viruses. Its use is particularly promising in patients undergoing immunosuppressive therapy, such as those after a stem cell transplant. Chimerix aims to develop innovative and effective drugs that help patients overcome serious diseases. With its unique business model and close collaboration with the research community, the company has already made promising progress and is an important player in the field of antiviral therapy and oncology. Chimerix is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Chimerix's Equity

Chimerix's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Chimerix's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Chimerix's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Chimerix's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Chimerix’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Chimerix stock

The Equity of Chimerix is 121.68 M USD in 2026.

The Equity of Chimerix changed from 193.03 M USD to 121.68 M USD, representing a -36.96% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Chimerix since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Chimerix historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Chimerix

All Key Metrics — Chimerix